A5048650165- Hematopoietic Stem Cell Transplantation
- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Multiple Myeloma Research and Treatments
- Polyomavirus and related diseases
- Neutropenia and Cancer Infections
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Antifungal resistance and susceptibility
- Cytomegalovirus and herpesvirus research
- Renal Transplantation Outcomes and Treatments
- Viral-associated cancers and disorders
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Fungal Infections and Studies
- Histone Deacetylase Inhibitors Research
- Mesenchymal stem cell research
- Protein Degradation and Inhibitors
- Lung Cancer Treatments and Mutations
- Pneumocystis jirovecii pneumonia detection and treatment
- Immunodeficiency and Autoimmune Disorders
- Childhood Cancer Survivors' Quality of Life
American University of Beirut Medical Center
2016-2024
American University of Beirut
2015-2023
Sorbonne Université
2012-2023
Assistance Publique – Hôpitaux de Paris
2012-2023
Institut Paoli-Calmettes
2011-2022
Université Paris-Sud
2022
Centre National de la Recherche Scientifique
2022
Institut de Chimie Moléculaire et des Matériaux d'Orsay
2022
Université Paris-Saclay
2022
Institut Pprime
2006-2018
To investigate the impact of prior-to-transplantation azacitidine (AZA) on patient outcome after allogeneic stem-cell transplantation (alloSCT) for myelodysplastic syndrome (MDS).Of 265 consecutive patients who underwent alloSCT MDS between October 2005 and December 2009, 163 had received cytoreductive treatment prior to transplantation, including induction chemotherapy (ICT) alone (ICT group; n = 98), AZA (AZA 48), or preceded followed by ICT (AZA-ICT 17). At diagnosis, 126 (77%) an excess...
Recently, the administration of high-dose cyclophosphamide (Cy) after T cell–replete haploidentical stem cell infusion has been reported to be feasible and effective. In original study, bone marrow (BM) was used as source cells. Here, we retrospectively analyzed use BM versus peripheral blood cells (PBSCs) in a cohort patients receiving transplantation nonmyeloablative conditioning regimen with postinfusion Cy. PBSC groups, incidence acute graft-versus-host disease (GVHD) 33% 25%,...
BACKGROUND Sorafenib has shown encouraging results in patients with Fms‐like tyrosine kinase 3 (FLT3)‐positive acute myeloid leukemia. Its role after allogeneic stem cell transplantation (HSCT) been reported a few cases results. METHODS The authors describe the use of sorafenib as maintenance agent HSCT 27 FLT3‐positive RESULTS median age was 46 years (range, 15‐57 years). introduced at 70 days 29‐337 days) HSCT. treatment duration 8.4 months 0.2‐46 months). Eleven experienced toxicities,...
It has recently been shown that a T cell-replete allogeneic (allo) hematopoietic stem cell transplantation (HSCT) from haploidentical donor (haplo-ID) could be valid treatment for hematological malignancies. However, little data exist concerning older populations. We provided to 31 patients over the age of 55 years haplo-ID and compared their outcomes with same ages who underwent matched related (MRD) or an unrelated (UD). All 3 groups were comparable, except conditioning. Patients in group...
We retrospectively analyzed outcomes of a CD34(+)-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 10(9)/L, and/or platelets ≤30 hemoglobin ≤8.5 g/dL). The interval between transplantation and SCB was 5 months (range, 2 228). number CD34(+) CD3(+) cells were 3.4 10(6)/kg (.96 8.30) 9 10(3)/kg body weight 70), respectively. Hematological improvement observed 81%...
The results of conventional allogeneic stem cell transplantation (SCT) in refractory hematologic malignancies are poor. Sequential strategies have shown promising acute myelogenous leukemia (AML), but not been validated a haploidentical (Haplo) transplant setting. We developed new sequential approach combining chemotherapy with broad antitumor activity (thiotepa 10 mg/kg, etoposide 400 mg/m2, and cyclophosphamide 1600 mg/m2 from day -15 to -10), followed after 3 days rest by...
The optimal combination of fludarabine, busulfan, and antithymocyte globulin (ATG) for reduced-intensity conditioning (RIC) transplantation has not been established. ATG plays a pivotal role in the prevention graft-versus-host disease (GvHD), but it is associated with higher relapse rate an elevated incidence infections when high doses are used.The authors retrospectively compared 2 different combined fludarabine busulfan 229 adult patients who underwent at their institution. was...
The prognosis of patients with acute myeloid leukemia in whom primary treatment fails remains very poor. In order to improve such patients' outcome, we conducted a phase 2, prospective, multicenter trial test the feasibility new sequential regimen, combining short course intensive chemotherapy and reduced intensity-conditioning before allogeneic stem-cell transplantation. Twenty-four (median age, 47 years) failure were included. Cytogenetic risk was poor 15 (62%) intermediate nine (38%)....